Investors-Beijing Avistone Biotechnology Co., Ltd.

You Are Leaving Avistone's Website

You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.

Cancel Continue

Home

FUND RAISING

Series B+ Funding

Series B Funding

Series A Funding


Series B+ Funding

In December 2024, Beijing Avistone Biotechnology Co.,Ltd. completed over $35 million from Beijing Medical and Health Care Industry Investment Fund (Limited Partnership) and Beijing Daxing District Industrial Development Fund.

Series B Funding

In December 2023, Beijing Avistone Biotechnology Co.,Ltd. completed over $140 million from CS Capital, IDG Capital, Yanchuang Capital, Cathy Capital, and the existing stakeholder Bain Capital continued to increase its investment.